Swedish study shows fully vaccinated are protected against severe COVID-19
Researchers evaluate the risk of severe Omicron infections in several risk categories defined by sex, age, comorbidities, and vaccination status. // 8.2.2022
About vaccines
Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar
BACKGROUND Qatar has been experiencing a large SARS-CoV-2 Omicron (B.1.1.529) wave that started on December 19, 2021. We assessed duration of protection of BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines after second dose and after third/booster dose against symptomatic Omicron infection and against COVID-19 hospitalization and death, between December 23, 2021 and February 2, 2022. // 8.2.2022
Effectiveness of Covid-19 Vaccines against the SARS-COV-2-Delta (B.1.617.2) in China-A Real World Study
Abstracts Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta (B.1.617.2) variant is highly transmissible and has contributed to a surge in cases globally. This study aimed to explore the potential of vaccines against SARS-CoV-2 delta (B.1.617.2) variant in China. // 8.2.2022
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by Omicron and Delta Variants
This case-control study uses data from the Centers for Disease Control and Prevention Increasing Community Access to Testing platform to estimate the association between receipt of 3 doses of Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273 vaccine, compared with 2 doses or unvaccinated, and... // 21.1.2022
Increased household transmission and immune escape of the SARS-CoV-2 Omicron variant compared to the Delta variant: evidence from Norwegian contact tracing and vaccination data
We compared the secondary attack rate (SAR) of the SARS-CoV-2 Omicron and Delta variants in households using contact tracing data. Omicron SAR was higher (41%) than Delta (35%), likely due to immune evasion. Booster dose reduces risk of infection but has limited effect on preventing Omicron transmission. // 8.2.2022
Study explores omicron-reactive T- and B- cell responses in COVID-19 vaccine recipients
A new study analyzes neutralizing antibodies and T-cell responses targeting the SARS-CoV-2 D614G, as well as some variants of concern. // 7.2.2022
Evaluating delayed vaccination schedules for protection against SARS-CoV-2
Researchers conducted an observational study to compare the humoral and cellular responses in health care workers who had received two doses of the Pfizer-BioNTech vaccine at standard (3 to 6 weeks) and delayed (8 to 16 week) intervals. // 7.2.2022
Study finds no strong evidence that COVID-19 vaccination is linked to menstrual changes
A new study reports on the incidence of changes in menstruation in women who have received the COVID-19 vaccine. // 18.11.2021
Prevalence of menstrual changes following vaccination against COVID-19
A new study investigates the relationship between COVID-19 vaccination and menstrual cycle disturbances. // 26.11.2021
Vaccine-induced immunity and prior infection effective in reducing COVID severity in reinfections
A recent study posted to the Research Square* preprint server and under consideration for inclusion in the journal Scientific Reports assessed the epidemiology of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) reinfections. // 6.2.2022
Greater neutralizing titers observed in vaccinated individuals with breakthrough Omicron infection
Researchers assess the neutralizing power of plasma samples collected from Omicron convalescent individuals who were either vaccinated or unvaccinated. // 6.2.2022
Booster dose of Pfizer-BioNTech COVID vaccine protects elderly against Omicron
Researchers discuss the impact of mRNA booster immunization on the neutralizing activity against the SARS-CoV-2 Omicron variant in the elderly. // 6.2.2022
mRNA booster vaccination shown to induce robust neutralizing antibodies against SARS-CoV-2 omicron variant
Scientists recently assessed the immunogenicity of a third booster dose of COVID-19 vaccines against SARS-CoV-2 variants. // 4.2.2022
COVID-19 Vaccination is Associated with Decreasing Cases, Hospitalizations, and Deaths Across Age Groups and Variants over 9 months in Switzerland
Recent studies assessing COVID-19 vaccine efficacy at the population level found counterintuitive results, such as positive associations between vaccination and infections or deaths. These ecological studies have limitations, including too short observation periods, focusing on infections, and not controlling for age groups and dominant variants. // 3.2.2022
Do COVID-19 vaccinations increase the length of the menstrual cycle?
In this interview, we speak to Professor Alison Edelman about her latest research that investigated the effects COVID-19 vaccinations have on the menstrual cycle. // 4.2.2022
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa | NEJM
Correspondence from The New England Journal of Medicine — Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa // 3.2.2022
Studying the efficacy of a SARS-CoV-2 vaccine booster dose
In a new study, a team of researchers assessed the efficacy of booster doses of Ad26.COV2.S (Jansen) SARS-CoV-2 vaccine. // 3.2.2022
Evaluating vaccine effectiveness and determining differences across demographic and clinical risk factors of COVID-19
Researchers assessed the effectiveness of COVID-19 vaccines against the manifestations of SARS-CoV-2 symptoms across different cohorts. // 2.2.2022
Study shows mRNA booster dose eliminates immune escape observed with SARS-CoV-2 Omicron
Researchers examined total and neutralizing antibodies to the spike protein of SARS-CoV-2, and neutralizing antibodies against Washington-1 (WA-1) and variants of concern (VOC) including Beta, Delta, and Omicron in a longitudinal cohort. // 31.1.2022
Study assesses anti-SARS-CoV-2 antibody response to mRNA-1273 vaccination over time
A new study has assessed the antibody responses to the mRNA-1273 Moderna vaccine over time. // 31.1.2022
COVID-19 vaccination does not impair fertility, suggests BU study
New findings by Boston University School of Public Health investigators indicate that COVID-19 vaccination does not impair fertility-;but males who become infected by the coronavirus may experience short-term reduced fertility. //21.1.2022
Vaccine-induced immunological memory is similar for Omicron and Delta SARS-CoV-2 variants
A new study by Norwegian researchers suggests that vaccine-induced immunological memory and the activation of recall responses in the body yields similar coverage for Omicron and Delta variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). // 31.1.2022
COVID-19 vaccines elicit cross-reactive antibodies against endemic coronaviruses
Researchers study the interaction between immunity to endemic coronaviruses and SARS-CoV-2. // 30.1.2022
Escape from vaccine-induced immunity likely contributed to rapid rise of SARS-CoV-2 Omicron
Researchers investigate whether the SARS-CoV-2 Omicron variant is more likely to infect vaccinated individuals than the SARS-CoV-2 Delta variant. // 30.1.2022
COVID-19 vaccination does not affect fertility outcomes in patients undergoing in-vitro fertilization
Vaccination against COVID-19 did not affect fertility outcomes in patients undergoing in-vitro fertilization (IVF), a new study has found. // 27.1.2022
Evaluating the effectiveness of vaccination on the case fatality rate for COVID-19 infection
A recent study was published where CFR was assessed for COVID-19 vaccine effectivity // 27.1.2022
Cross-recognition of SARS-CoV-2 vaccine-elicited T cell responses among different variants
In a new study, researchers evaluated SARS-CoV-2 vaccination-induced T cell responses cross-recognition among the early and novel SARS-CoV-2 variants. // 26.1.2022
COVID-19 vaccine does not lead to infertility in either men or women
In a recent prospective cohort study accepted to the American Journal of Epidemiology, researchers observed links between female and male coronavirus disease 2019 (COVID-19) vaccination and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and fecundability or the per-cycle likelihood of conception in North American couples seeking to conceive. // 26.1.2022
SARS-CoV-2 infection and vaccination-induced T cells cross-recognize Omicron
In a recent study posted to the Nature In Review* preprint server, researchers performed a comprehensive, in-depth comparison of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell epitope repertoire following natural infection of coronavirus disease 2019 (COVID-19) compared to messenger ribonucleic acid (mRNA) vaccinations. // 25.1.2022
A prospective cohort study of COVID-19 vaccination, SARS-CoV-2 infection, and fertility
Some reproductive-aged individuals remain unvaccinated against COVID-19 due to concerns about potential adverse effects on fertility. We examined the associations of COVID-19 vaccination and SARS-CoV-2 infection with fertility among couples trying to conceive spontaneously using data from an interne … // 20.1.2022